(11) EP 0 584 452 B1

(12) EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention of the grant of the patent:

31.07.2002 Bulletin 2002/31

(51) Int Cl.7: **C12N 15/12**, C12N 15/62, C07K 2/00, C12N 5/10

(21) Application number: 93105718.6

(22) Date of filing: 07.04.1993

(54) Novel amyloid precursor proteins and methods of using same

Neue Amyloid-Precursor-Proteine und Verfahren zur deren Verwendung Nouveaux précurseurs de protéines amyloides et méthodes les utilisant

(84) Designated Contracting States:

AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT
SE

(30) Priority: 01.05.1992 US 877675

(43) Date of publication of application: 02.03.1994 Bulletin 1994/09

(73) Proprietor: AMERICAN CYANAMID COMPANY Wayne, NJ 07470-8426 (US)

(72) Inventors:

 Vitek, Michael Peter Waldwick, New Jersey 07463 (US)

Jacobsen, Jack Steven
 Ramsey, New Jersey 07446 (US)

(74) Representative:

Wächtershäuser, Günter, Prof. Dr. Patentanwalt, Tal 29 80331 München (DE)

(56) References cited:

EP-A- 0 451 700 WO-A-88/03951 WO-A-90/01540 WO-A-90/14840

- SCIENCE vol. 248, 1990, pages 492 495 S.S.
   SISODIA ET AL.; 'Evidence that beta-amyloid protein in Alzheimer's Disease is not derived by normal processing'
- JOURNAL OF BIOLOGICAL CHEMISTRY vol. 267, 1992, pages 25602 - 25608 S.R.
   SAHASRABUDHE ET AL.; 'Release of amino-terminal fragments from amyloid precursor protein reporter and mutated derivatives in cultured cells'

EP 0 584 452 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

### Description

10

30

35

40

50

55

# **BACKGROUND OF THE INVENTION**

**[0001]** Throughout this application various references are referred to within parentheses. Disclosures of these publications in their entirety are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains. Full bibliographic citations for these references may be found at the end of this application, immediately preceding the claims.

[0002] Abnormal accumulation of extracellular amyloid in plaques and cerebrovascular deposits are characteristic in the brains of individuals suffering from Alzheimer's disease (AD) and Down's Syndrome (Glenner and Wong, BBRC, 120:885-890, 1984; Glenner & Wong, BBRC, 120:1131-1153, 1984). The amyloid deposited in these lesions, referred to as beta amyloid peptide (BAP), is a poorly soluble, self-aggregating, 39 to 43 amino acid (aa) protein which is derived via proteolytic cleavage from a larger amyloid precursor protein (APP) (Kang et al., Nature 325:733-736, 1987) BAP also is thought to be neurotoxic (Yankner et al., Science 245:417-420, 1990). APP is expressed as an integral transmembrane protein (Dyrks et al., EMBO. J., 7:949-957, 1989) and is normally proteolytically cleaved by "secretase" (Sisodia et al., Science, 248:492-495, 1990; Esch et al., Science, 248:1122-1124) between BAP-16K (lysine) and 17L (leucine). Cleavage at this site therefore precludes amyloidogenesis (Palmert et al., BBRC, 156:432-437, 1988) and results in release of the amino-terminal APP fragment which is secreted into tissue culture medium (Sisodia et al., ibid, Esch, et al., ibid). Three major isoforms of APP (APP-695, APP-751 and APP-770 amino acids) are derived by alternative splicing (Ponte, et al., Nature 331:528-530, 1988), are expressed as integral transmembrane proteins (Kang et al., Nature 325:733-736, 1987; Dyrks et al., EMBO J. 7:949-957, 1988).

**[0003]** Even though both APP-770 and -751 isoforms contain a protease inhibitor domain, it is the secreted portion of APP-751 (also known as Protease Nexin II (Van Nostrand et al., Science, 248:745-748, 1990) which is thought to be involved in cell adhesion (Schubert et al., Neuron, 3:689-694, 1989), remodeling during development, coagulation (Smith et al., Science, 248:1126-1128, 1990) and wound repair.

[0004] Although the mechanisms underlying abnormal proteolytic processes which result in BAP extraction from APP are poorly understood, it is thought to be central to the pathogenesis (Selkoe, Neuron, 6:487-498, 1991; Isiura, J. Neurochem. 56:363-369, 1991) and memory loss (Flood, et al., Proc. Natl. Acad. Sci. 88:3363-3366, 1991) associated with Alzheimer's Disease.

[0005] Based on the observations that (a) amyloid plaques develop in AD brains, (b) a major component of plaques is BAP, (c) BAP is generated by proteolytic cleavage of APP protein, (d) mRNA levels of specific APP isoforms increase in AD suggesting that more APP protein is expressed, (e) APP point mutations which are thought to possibly after normal processing have been identified in Familial AD (FAD) and "Dutch" disease, (f) injection of BAP into the brains of rodents both form lesions reminiscent of plaque pathology and result in memory deficits, and (g) the detection of plaque-like amyloid deposits in the brains of transgenic mice expressing human APP, it is important to understand how APP is processed to generate BAP.

# **SUMMARY OF THE INVENTION**

[0006] This invention provides novel nucleic acid molecules which encode amyloid precursor muteins and the polypeptides encoded therefrom. Also provided are host vector systems useful for the recombinant production of the recombinant polypeptides in procaryotic and eucaryotic systems. Cells comprising the host vector systems of this invention as well as methods of recombinantly producing these polypeptides are provided by this invention. Further provided is a method to detect the recombinant polypeptides of this invention. Further provided is a method of screening for a compound which inhibits or augments the formation of  $\beta$ -amyloid protein.

### **BRIEF DESCRIPTION OF THE FIGURES**

[0007] Figure 1: Schematic representation of APP-REP 751. APP-REP 751 represents a cleavable APP substrate system which contains target sequences of BAP including normal flanking regions (not to scale). The APP-REP protein is marked with a 276 amino acid deletion (corresponding to APP-751 beginning at Xhol through to and including the glycine codon at 15 amino acid residues N-terminal to BAP) and the insertion of sequences encoding N- and C- terminal reporter epitopes. Substrate P (SP) reporter epitope (RPKPQQFFGLM) is inserted at the Xhol site. Met-enkephaline (ME) reporter epitope (YGGFM) is inserted at the C-terminus of APP. The resulting construct encodes 492 amino acids (see Figure 2).

[0008] Figure 2: Schematic representation depicting the construction of APP-REP from APP-751 cDNA. Partial representing N- and C-terminal regions of APP-REP were cloned separately as illustrated below. The N-terminal partial

was constructed by ligating sequences encoding substance P (SP) to an N-terminal fragment of APP cDNA. The C-terminal partial was constructed by PCR amplification using the corresponding portion of APP cDNA to introduce novel ends including the Met-enkephalin (ME) reporter epitope. A functional APP-REP 751 clone was obtained by subcloning the partials as indicated. EcoRI (E), XhoI (X), HindIII (H), BamHI (B), Sall (S), Xbal (Xb).

[0009] Figure 3: Epitope mapping of APP-REP 751 expressed in COS-1 cells. Immunoprecipitation analysis of cell lysate and conditioned medium using the SP (anti-N-terminal substance P reporter) and M3 (anti-C-terminal APP) antisera. Lanes 1 and 2, cell lysate immunoprecipitated with SP and M3 antisera, respectively; lanes 3 and 4, conditioned medium immunoprecipitated with M3 and SP antisera, respectively; lanes 5 and 6, conditioned medium of control cells transfected with vector DNA immunoprecipitated with SP and M3 antisera, respectively; lane M, molecular weight markers.

**[0010]** Figure 4: Pulse-chase analysis of APP-REP 751. Immunoprecipitation of cell lysate (A) and CM (B). COS-1 cells were pulsed with [35S]-methionine for 15 minutes and chased using cold methionine for 0, 0.5, 1, 1.5, 2 and 4 hours (lanes 1 to 6). Lanes 7, 8 and 9 are chase intervals of 0, 1 and 2 hour for control cells transfected with vector DNA. Lane M, molecular weight markers.

[0011] Figure 5: Epitope mapping and comparative expression of APP-REP 751, BAP<sub>E22Q</sub> and BAP<sub> $\Lambda$ </sub><sup>11-28</sup>.A, Schematic representation of relevant BAP (boxed) and flanking amino acid sequences of APP-REP 751, BAP<sub>E22Q</sub> and BAP<sub> $\Lambda$ 11-28</sub> juxtaposed against the putative transmembrane domain (shadowed). B-F, Immunoprecipitation analysis with antibodies recognizing indicated substance P (SP), KPI domain (KPI), C-terminal APP (M3) or Met-enkephalin (ME) epitopes; Lane M, molecular weight marker. B, Conditioned medium obtained from COS-1 cells expressing APP-REP 751 (lane 3), BAP<sub>E22Q</sub>(lanes 4, 6 and 8), BAP<sub> $\Lambda$ 11-28</sub>(lanes 5, 7 and 9) or control cells with (lane 2) or without (lane 1) transfection with vector DNA. C, Cell lysates obtained from COS-1 cells expressing APP-REP BAP<sub>E22Q</sub>(lanes 1, 4 and 7), BAP<sub> $\Lambda$ 11-22</sub> (lanes 2, 5 and 8) and control cells transfected with vector DNA (lanes 3, 6 and 9). D, Accumulation of secreted APP-REP 751 fragments in the conditioned medium obtained from COS-1 cells expressing APP-REP 751 (lanes 2 and 6), BAP<sub>E22Q</sub> (lanes 3 and 8), BAP<sub> $\Lambda$ 11-28</sub>(lanes 4 and 7), or control cells transfected with vector DNA (lanes 1 and 5), were pulsed with [ $\Lambda$ 55]-methionine and chased for 45 (lanes 1-4) or 90 (lanes 5-8) minutes with cold methionine. E, Accumulation of secreted APP-REP fragments in the conditioned medium obtained from stable (Chinese hamster ovary cells; lanes 1-4) and transient (COS-1 cells; lanes 5 and 6) expression of APP-REP 751 (lanes 2 and 5), BAP<sub> $\Lambda$ 11-28</sub> (lanes 3 and 6), BAP<sub> $\Lambda$ 22Q</sub> (lane 4), or control cells transfected with vector DNA (lane 1).

[0012] Figure 6: Peptide mapping and sequencing of fragments secreted into the conditioned medium obtained from Chinese hamster ovary cells stably expressing APP-REP 751, BAP $_{\rm E22Q}$  and BAP $_{\rm \Delta11-28}$ . A, Schematic representation depicting the APP-REP 751 and related derivative indicating the cleavage products and relevant carboxy-terminal fragments derived from treating the secreted fragments either with BNPS-Skatole (B) or cyanogen bromide. Downward-or upward-facing arrows represent BNPS-Skatole and cyanogen bromide cleavage sites, respectively. Amino acid lengths of relevant fragments for mapping or sequencing are given. B, BNPS-Skatole treatment of fragments secreted into the conditioned medium obtained from CHO cells stably expressing APP-REP 751 or BAP $_{\rm \Delta11-28}$ . Mixture of conditioned medium containing APP-REP and BAP $_{\rm \Delta11-28}$ (lane 1), or BAP $_{\rm \Delta11-28}$ (lane 2) and APP-REP 751 (lane 3) alone. [0013] Figure 7: Nucleotide and amino acid sequence of the APP-REP 751 protein.

[0014] Figure 8: Nucleotide sequence of APP 770 which also is available from the Genebank data base under accession number Y00264.

# **DETAILED DESCRIPTION OF THE INVENTION**

10

30

35

40

45

50

**[0015]** This invention provides a nucleic acid molecule encoding an amyloid precursor mutein, wherein the nucleic acid molecule comprises, from the 5' end to the 3' end, a nucleic acid sequence encoding a marker and a nucleic acid sequence encoding the amino terminus of APP up to but not including the sequences that encode BAP. These nucleic acid molecules may include, but are not limited to the nucleic acid molecules selected from the group consisting of pCLL983, pCLL935, pCLL934 and pCLL913.

**[0016]** This invention also provides a nucleic acid molecule encoding an amyloid precursor mutein, wherein the nucleic acid molecule comprises, from the 5' end to the 3' end a nucleic acid sequence encoding BAP and a nucleic acid sequence encoding a marker. These nucleic acid molecules may include, but are not limited to the nucleic acid molecules selected from the group consisting of pCLL947, pCLL914, pCLL937, pCLL949 and pCLL957.

**[0017]** Further provided by this invention is a nucleic acid molecule which comprises the nucleic acid molecules defined hereinabove to each other. Method of ligating are well known to those of skill in the art. These nucleic acid molecules may include, but are not limited to the nucleic acid molecules selected from the group consisting of pCLL618, pCLL619, pCLL620, pCLL600, pCLL604, pCLL962, pCLL989, pCLL987, pCLL990, pCLL988, pCLL601, pCLL602, pCLL603, pCLL604, pCLL605, pCLL606 and pCLL607. These nucleic acid molecules are described in Table 3.

[0018] As used herein, the term "amyloid precursor mutein" is intended to encompass an amyloid precursor protein that is mutated, i.e., it is derived from a nucleic acid molecule which has changes in its primary structure as compared

to wild-type amyloid precursor protein (APP). Wild-type APP exists in three isoforms, thus, the nucleic acid molecule is changed in its primary structure for each of the three isoforms of wild-type APP. As is known to those of skill in the art, a mutation may be a substitution, deletion, or insertion of at least one nucleotide along the primary structure of the molecule. The mutations which are encompassed by this invention are the result of saturation mutagenesis in the regions of APP which are susceptible to cleavage by endoproteolytic enzymes. These mutations include deletions of nucleic acids encoding particular amino acids, substitution of nucleic acid sequences encoding one amino acid for a different amino acid and addition of nucleic acid sequences encoding additional amino acids not present in the wild type APP sequence. The term "marker" encompasses any substance capable of being detected or allowing the nucleic acid or polypeptide of this invention to be detected. Examples of markers are detectable proteins, such as enzymes or enzyme substrates and epitopes not naturally occurring in wild-type APP that are capable of forming a complex with an antibody, e.g. a polyclonal or monoclonal antibody. In the preferred embodiment of this invention, the marker is an epitope capable of being detected by a commercially available antibody. In one embodiment, the marker is an epitope capable of being detected by a monoclonal antibody directed to the Substance P, the Met-enkephalin or the c-myc epitope. In the most preferred embodiment of this invention, the marker is the c-myc epitopic region.

10

30

35

40

45

50

[0019] The term "BAP region" is defined as the region of APP wherein endoproteolytic cleavage will yield the aminoterminus and the carboxy-terminus of the BAP which is deposited as plaques and cerebrovascular amyloid in Alzheimer's disease brain. The function of the "BAP region" is to give rise to BAP which may function as a neurotoxic and/or neurotrophic agent in the brain and as other functionalities ascribed to BAP. The "BAP region" may also be endoproteolytically cleaved by enzymes. Such enzymes may include, but are not limited to the enzymes multicatalytic prtenase, propyl-endopeptidase, Cathepsin-B, Cathepsin-D, Cathepsin-L, Cathepsin-G or secretase. Secretase cleaves between lysine-16 (K-16) and leucine-17 (L-17) where full length BAP comprises the amino acid sequence DAEFRH-DSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA. Thus, for the purposes of this invention, the preferred embodiment is a cDNA which encodes an RNA which is translated into a protein which is the substrate for endoproteolytic activities which generate BAP.

[0020] In addition, for the purposes of this invention, the nucleic acid molecule may be DNA, cDNA or RNA. However, in the most preferred embodiment of this invention, the nucleic acid is a cDNA molecule.

[0021] This invention also encompasses each of the nucleic acid molecules described hereinabove inserted into a vector so that the nucleic acid molecule may be expressed, i.e., transcribed (when the molecule is DNA) and translated into a polypeptide in both procaryotic and eucaryotic expression systems. Suitable expression vectors useful for the practice of this invention include pSVL (Pharmacia), pRCRSV (Invitrogen), pBluescript SK+ (Stratagene), pSL301 (Invitrogen), pUC19 (New England Biolabs). However, in the preferred embodiment of this invention, the vector pcDNA1-neo is the expression vector for expression in eucaryotic cells. As is well known to those of skill in the art, the nucleic acid molecules of this invention may be operatively linked to a promoter of RNA transcription, as well as other regulatory sequences. As used herein, the term "operatively linked" means positioned in such a manner that the promoter will direct the transcription of RNA off of the nucleic acid molecule. An example of a promoter is the human cytomegalovirus promoter. The vectors of this invention preferably are capable of transcribing and/or translating nucleic acid in vitro or in vivo. The recombinant polypeptides produced from the expression of the nucleic acid molecules of this invention are also provided.

[0022] A host vector system for the production of the recombinant polypeptides described hereinabove and for expressing the nucleic acid molecules of the subject invention are provided. The host vector system comprises one of the vectors described hereinabove in a suitable host. For the purpose of the invention, a suitable host may include, but is not limited to a eucaryotic cell, e.g., a mammalian cell, a yeast cell or an insect cell for baculovirus expression. Suitable mammalian cells may comprise, but are not limited to Chinese hamster ovary cells (CHO cells), African green monkey kidney COS-1 cells, and ATCC HTB14 (American Type Tissue Culture). Most preferably, the cell lines CRL 1650 and CRL 1793 are used. Each of these are available from the American Type Culture Collection (ATCC) 12301 Parklawn Drive, Rockville, Maryland U.S.A. 20852. Suitable procaryotic cell may include, but are not limited to bacteria cells, HB101 (Invitrogen), MC1061/P3 (Invitrogen), CJ236 (Invitrogen) and JM109 (Invitrogen). Accordingly, the procaryotic or eucaryotic cell comprising the vector system of this invention is further provided by this invention.

[0023] As is known to those of skill in the art, recombinant DNA technology involves insertion of specific DNA sequences into a DNA vehicle (vector) to form a recombinant DNA molecule which is capable of being replicated in a host cell. Generally, but not necessarily, the inserted DNA sequence is foreign to the recipient DNA vehicle, i.e., the inserted DNA sequence and DNA vector are derived from organisms which do not exchange genetic information in nature, or the inserted DNA sequence comprises information which may be wholly or partially artificial. Several general methods have been developed which enable construction of recombinant DNA molecules. For example, U.S. Patent No. 4,237,224 to Cohen and Boyer describes production of such recombinant plasmids using processes of cleavage of DNA with restriction enzymes and joining the DNA pieces by known method of ligation.

[0024] These recombinant plasmids are then introduced by means of transformation or transfection and replicated in unicellular cultures including procaryotic organisms and eucaryotic organisms and eucaryotic cells grown in tissue

culture. Because of the general applicability of the techniques described therein, U.S. Patent No. 4,237,224 is hereby incorporated by reference into the present specification. Another method for introducing recombinant DNA molecules into unicellular organisms is described by Collins and Hohn in U.S. Patent No. 4,304,863 which is also incorporated herein by reference. This method utilized a packaging, transduction system with bacteriophage vectors (cosmids).

**[0025]** Nucleic acid sequences may also be inserted into viruses, for example, a vaccinia virus or a baculovirus. Such recombinant viruses may be generate, for example, by transfection of plasmids into cells infected with virus, Chakrabarti et al, (1985) Mol. Cell Biol. 5:3402-3409.

[0026] Regardless of the method used for construction, the recombinant DNA molecule is preferably compatible with the host cell, i.e., capable of being replicated in the host cell either as part of the host chromosomes or as an extrachromosomal element. The recombinant DNA molecule or recombinant virus preferably has a marker function which allows the selection of the desired recombinant DNA molecule(s) or virus, e.g., baculovirus. In addition, if all of the proper replication, transcription and translation signals are correctly arranged on the recombinant DNA molecule, the foreign gene will be properly expressed in the transformed or transfected host cells.

10

35

40

45

50

55

[0027] Different genetic signals and processing events control gene expression at different levels. For instance, DNA transcription is one level, and messenger RNA (mRNA) translation is another. Transcription of DNA is dependent upon the presence of a promoter which is a DNA sequence that directs the binding of RNA polymerase and thereby promotes RNA synthesis. The DNA sequences of eucaryotic promoters differ from those of procaryotic promoters. Furthermore, eucaryotic promoters and accompanying genetic signals may not be recognized in or may not function in a procaryotic system.

[0028] Similarly, translation of mRNA in procaryotes depends upon the presence of the proper procaryotic signals which differ from those of eucaryotes. Efficient translation of mRNA in procaryotes requires a ribosome binding site called the Shine-Dalgarno (SD) sequence on the mRNA. For a review on maximizing gene expression, see Roberts and Lauer (1979) Methods in Enzymology 68:473.

**[0029]** Many other factors complicate the expression of foreign genes in procaryotes even after the proper signals are inserted and appropriately positioned. One such factor is the presence of an active proteolytic system in <u>E. coli</u> and other bacteria. This protein-degrading system appears to destroy foreign proteins selectively. A tremendous utility, therefore, would be afforded by the development of a means to protect eucaryotic proteins expressed in bacteria from proteolytic degradation. One strategy is to construct hybrid genes in which the foreign sequence is ligated in phase (i. e., in the correct reading frame) with a procaryotic structural gene.

30 [0030] Expression of this hybrid gene results in a recombinant protein product (a protein that is a hybrid of procaryotic and foreign amino acid sequences).

[0031] Successful expression of a cloned gene requires efficient transcription of DNA, translation of the mRNA and in some instances post-translation modification of the protein. Expression vectors have been developed to increase protein production from the cloned gene. In expression vectors, the cloned gene is often placed next to a strong promoter which is controllable so that transcription can be turned on when necessary. Cells can be grown to a high density and then the promoter can be induced to increase the number of transcripts. These, if efficiently translated, will result in high yields of polypeptide. This is an especially valuable system if the foreign protein is deleterious to the host cell.

[0032] Several recombinant DNA expression systems are described below in the Experimental Procedures section for the purpose of illustration only, and these examples should not be construed to limit the scope of the present invention.

**[0033]** A method for producing a recombinant polypeptide described hereinabove, is also provided. This method comprises growing the host cell containing the nucleic acid of this invention and/or the host vector system of this invention under suitable conditions, permitting production of the polypeptide and recovering the resulting recombinant polypeptide produced.

[0034] A method of detecting in a sample the presence of any of the recombinant polypeptides described hereinabove is further provided by this invention. In the preferred embodiment of this invention, the marker is an epitope directed against an antibody, the epitope of which is not present in the wild-type polypeptide or APP derivative. This method comprises obtaining a sample suspected of containing the polypeptide and contacting the sample with an antibody directed to the marker. The contacting is done under suitable conditions to favor the formation of an antibody-epitope (i.e., antigen) complex, and detecting the presence of any complex so formed. The presence of complex being a positive indication that the recombinant polypeptide is in the sample. In one embodiment of this invention, the antibody is a mouse antibody. In another embodiment of this invention, the antibody is a human antibody. In the most preferred embodiment, the mouse or human antibody is either a mouse or human monoclonal antibody.

**[0035]** The antibody is labeled with a detectable marker selected from the group consisting of radioisotopes, dyes, enzymes and biotin. For the purposes of this invention, suitable radioisotopes include, but are not limited to, <sup>32</sup>P, <sup>35</sup>S, <sup>131</sup>I and <sup>125</sup>I.

[0036] Suitable samples for the practice of this invention include, but are not limited to conditioned media, cell lysates and cellular organelle fractions.

[0037] The method of this invention may utilize the recombinant polypeptide for the detection of drugs or compounds that inhibit or augment the activity of proteolytic enzymes which cleave APP to generate BAP fragments. For the purposes of example only, a recombinant polypeptide which contains a Substance-P marker epitope on the amino-terminal side of BAP and a Met-enkephalin marker epitope on the carboxy-terminal side of BAP. Using commercially available RIA kits (Peninsula), one can measure the amount of amino-marker and carboxy-marker in any given sample. Since endoproteolytic activity is shown (see Figure 3) to allow the release of amino-terminal fragments of APP containing the amino-marker into the conditioned media while carboxy-terminal APP fragments containing the carboxy-marker remain associated with the cell, then RIA measures the amount of amino-marker in the conditioned medium as a direct result of endoproteolytic cleavage activity between the marker epitopes preferably within the "BAP region". Using this RIA to the amino-marker, the effect of potential drugs designed to modify endoprotease activity can be tested comparing the level of amino-marker in untreated and endoprotease-inhibitor treated samples. If a difference in non-treated and treated samples is found, then the position of the cleavage or lack of cleavage can be verified as with the procedures used in Figures 3 to 6. Thus, the qualitative and quantitative aspects of endoproteolytic activity and its inhibition on the recombinant APP mutein is evaluated. The amino-marker also is an enzyme such as beta-galactosidase which would be released in the conditioned media by the action of an appropriate endoprotease. Cell free samples of conditioned media containing the liberated enzyme converts a chromogenic substrate into the appropriately colored product (Blue for X-gal and Yellow for ONPG) which is measured spectrophotometrically. Inhibitors of the appropriate endoprotease would inhibit the release of beta-galactosidase enzyme into the conditioned medium resulting in less colored product being observed.

[0038] It is a purpose of this invention to develop a cleavable APP substrate system which represents target sequences of BAP including normal flanking regions to provide recognition sequences for processing enzymes. The utilization of a common substrate for parallel strategies involving in vitro cleavage assays using cellular extracts, in vivo processing assays in tissue culture or bacterial cells, or in conjunction with a selection system aimed at cloning BAP-cleaving proteases (or other relevant proteins) is preferred.

**[0039]** A second purpose of this invention is to develop an APP substrate which is non-cleavable by secretase in order to better detect other putative abnormal processing events which are hypothesized to potentially either compete with secretase for limited substrate, or occur at much lower frequency than secretase and whose effects may be otherwise masked by the mass action of secretase. These are referred to as "secretase-minus mutants" in Table 4.

[0040] Third, secretase-cleavable and -noncleavable APP substrates would provide probes with which to investigate cellular post-translational modifications to APP in an attempt to determine the potential influence on normal secretase and abnormal BAP "clipping" activities. These areas include, among others, the consideration of various known APP point mutations, contribution by different cell/tissue types (normal- or AD-specific), the Kunitz Protease Inhibitor domain present in APP-770 and - 751 isoforms, APP phosphorylation and APP glycosylation.

[0041] These are referred to as "APP 717 mutations" or Dutch Disease Mutations in Table 5.

**[0042]** Fourth, the ability to detect specific APP proteolytic events, either the normal secretase or the abnormal BAP-generating activities, would enable the use of strategies which use phenotypic rescue as a marker for the cloning of potentially relevant and interesting proteases in tissue culture systems.

Overview of the APP-REP Strategy

10

30

35

40

45

50

55

[0043] To study secretase and BAP-generating pathways, portions of APP cDNA clones are used to engineer a panel of APP-REPorter (APP-REP) plasmids to express "marked" proteins representing each of the APP isoforms (and other APP/BAP sequence alterations; see below) in cultured cells. The system utilizes the marker Substance-P (SP) and Met-Enkephalin (ME) which are strategically placed, respectively, on amino- and carboxy-terminal sides of BAP. Proteolytic cleavage of APP-REP target substrate is determined by the electrophoretic sizing of resulting proteolytic fragments and immunological detection of APP-specific and SP and ME reporter epitopes. Deletion of a large central portion of APP sequence also makes APP-REP readily distinguishable from the endogenous APP isoforms based on size. Moreover, the resolution of detecting proteolytic cleavage at different positions within the APP-REP substrate protein is enhanced by working with shorter target substrates. Approximate location of cleavage is determined initially by fragment sizing and epitope mapping; the exact cleavage site is later determined by peptide mapping of affinity/ HPLC purified fragments and sequencing of peptide ends.

[0044] Plasmids also are derived from these constructs for developing similar strategies to express APP-REP protein in cell free reticulocyte transcription-translation and bacterial systems. Mutation of APP-REP secretase/BAPase cleavage site (by sequence substitution, deletion or FAD mutations) can reveal putative proteolytic activities associated with BAP formation including amino- and carboxy-BAPase activities which are predicted to result in altered product fragments lengths.

# FIRST SERIES OF EXPERIMENTS

**Bacterial Strains and Transformation** 

[0045] Transformation of commercially available frozen competent bacteria, maintenance and selection of transformants is according to the manufacturer. Strains HB101, DH5a or JM109 (Gibco-BRL) are used for the construction of APP-REP in pSK(+) (Stratagene, La Jolla, CA) and pSL 301 (Invitrogen, San Diego, CA). APP-REP is subsequently subcloned into the eucaryotic expression vector pcDNA-1-neo and amplified in MC1061/P3 (Invitrogen, San Diego, CA).

Plasmid Construction

10

30

35

40

45

50

55

[0046] A cassette approach is used to independently construct portions of the APP-REP plasmid (Figure 2). The Nterminal partial includes APP sequences through the Substance P (SP) epitope, while the carboxy-terminal (C-terminal) partial includes BAP (or sequence variations of BAP) through the Met-enkephalin (ME) epitope (Figure 1). A plasmid encoding the N-terminal cassette (either of the plasmids listed in Table 1A, which include pCLL983, pCLL935, pCLL934 and pCLL913) is constructed by ligating the EcoRI-Xhol fragment derived from each of the corresponding APP cDNAs listed in Table 1A, which include APP-695, APP-751 or two different APP-770 sequences, to a short synthetic Xhol-HindIII fragment encoding Substance P (amino acid 1-11). This product is then ligated into the EcoRI and HindIII sites of pSK(+). Plasmid encoding the carboxy-terminal (C-terminal) cassette (pCLL947) is constructed by cloning into the HindIII-BamHI sites of pSL301 a fragment containing BAP sequences which is amplified by polymerase chain reaction. [0047] The fragments feature a novel 5'-HindIII site beginning at lysine 638 of APP-751, native or modified BAP sequences, and additional full-length or truncated APP sequences. The C-terminal cassette provides APP C-terminal wild type sequences, truncations following the transmembrane domain of BAP sequence, an E to Q substitute at BAP as#22, or a G to A substitute at BAP aa#10 with the deletion of aa#11-28 and creation of a novel Ndel site. Each of the APP C-terminal variantes contain the additional Met-enkephalin sequences. Each of the resulting pSL301 Hindl-II-Sall fragments (including HindIII-BamHl coding region plus BAmHl-Sall polylinker sequences) is then isolated and ligated pairwise with each of the N-terminal cassettes by subcloning into the HindIII-Sall sites of the SK(+)-based plasmid to generate the panel of new plasmids identified in Table 2. Next, the polylinker of the CMV promotor driven eukaryotic expression vector, pcDNA-1-neo (pCLL601), was modified to accommodate the panel of plasmids listed in Table 2 of Xbal-Sall APP and APP-Rep fragments to create a second panel of plasmids listed in Table 3 for eukaryotic

[0048] Polylinker modification involves the substitution of the HindIII-Xbal fragment with a synthetic one which restores HindIII, destroys Xbal and introduces novel BamHI-XabI-Xho-Sall sites.

Tissue Culture Lines

**[0049]** All cells are obtained from American Type Culture Collection and maintained according to their recommendation. They include SV40-transformed African Green monkey kidney COS-1 cells (CRL 1650) for transient expression and Chinese hamster ovary CHO-1C6 (CRL 1973) for stable expression systems.

Transfection Procedure

**[0050]** Cells are seeded at a density of 2-3 X 10<sup>6</sup>/100 mm dish and transfected using Lipofectin (Gibco-BRL, Grand Island, NY) when ~75% confluent. Plasmid DNA (0.5-4 mg) is diluted in 450 ml of Opti-MEM (Gibco-BRL, Grand Island, NY), mixed with 450 ml containing 75-100 ml Lipofectin and the mixture incubated at room temperature for 20-30 minutes. Addition of DNA-Lipofectin mixture to cells, recovery phase and G418 selection (Gibco-BRL), when applicable, are according to the manufacturer's protocol. Cells and conditioned medium are harvested at 48-72 hours following transfection for assay of APP-REP expression.

Antisera

[0051] APP-specific antisera:anti-N-terminal APP, mouse monoclonal 22C11 (Boehringer-Mannheim Biochemicals, Indianapolis, IN) raised against a recombinant fusion protein expressing APP-695 (epitope mapped to aa 60-100); anti-KPI rabbit polyclonal, raised against recombinant protein encoded by the Hinfl fragment derived from APP-770; and anti-APP C-terminal rabbit polyclonal M3, raised against synthetic APP peptides corresponding to APP-770 amino acid residues 649-671. Reporter-specific antisera:anti-substance P, rabbit polyclonal, purchased from Peninsula, Belmont, CA; and anti-Met-enkephalin, rabbit polyclonal, purchased from Cambridge, Wilmington, DE.

[0052] Preparation of Radiolabeled APP-REP and Extraction from Conditioned Medium and Cell Lysates

[0053] APP-REP proteins transiently expressed in exponentially growing adherent cells (~4 x 10<sup>6</sup>) are radiolabeled by metabolic incorporation of [35S]-methionine as follows. Cell monolayers are washed twice with prelabeling medium (methionine-free D-MEM supplemented with glutamine, sodium pyruvate, antibiotics and 1% dialyzed fetal bovine serum (Gibco-BRL) and incubated for 15 minutes to 4 hours in prelabeling medium containing 150-450 uci[35S]-methionine (Amersham, 800Ci/mmol). If chased with cold methionine, the medium is removed following the pulse, the monolayer is washed with prelabeling medium and replaced with 3 ml of the same containing 1 mM cold methionine. [0054] The conditioned medium is recovered following radiolabeling by aspiration from plates and cell debris removed by centrifugation for 10 minutes at 4°C (-300xg). Conditioned medium is immediately supplemented with protease inhibitors (pepstatin A, 50 ug/ml; leupeptin, 50 ug/ml; aprotinin, 10 ug/ml; EDTA, 5 mM; PMSF, 0.25 mM) and immunoprecipitation buffer (IPB; Sisodia et al., 1990) for protein analysis. Briefly, 3 ml of CM is supplemented with 0.75 ml 5X IPB (250 mM Tris, pH 6.8; 750 mM NaCl; 25 mM EDTA; 2.5% Nonidet P40; 2.5% sodium deoxycholate) and incubated for 20 minutes at 4°C prior to use.

[0055] Lysates are prepared by washing the labeled cell monolayer twice with 5 ml pre-labeling medium and directly extracting cells in plates at 4° C with 3.75 ml 1X IPB (including protease inhibitors). Cells are scraped into the buffer, incubated for 20 minutes at 4°C and lysates clarified of cellular debris by centrifugation for 20 minutes at 10,000xg. [0056] For radioiodination of cell surface proteins, monolayers are chilled on ice, washed 3 times with 5 ml ice cold PBS and labeled at room temperature for 10 minutes following the addition of: 5 ml PBS containing 0.2 mCi lodine-125 (NEZ-033A, New England Nuclear), 0.25 ml lactoperoxidase (1 mg/ml distilled water, Sigma), 10 ul of hydrogen peroxide solution (freshly prepared by diluting 10 ml of 30% stock in 10 ml of PBS) added at 0, 3, 6, and 9 minutes of iodination. At 10 minutes, the supernatant is removed and cells gently washed with 10 ml of ice cold PBS (containing 10 mM Nal). Four ml of PBS is added, and CM and cell lysates are prepared as above.

# Immunoprecipitation Analysis

10

25

30

35

40

50

[0057] Aliquots of radiolabeled lysate or conditioned medium representing 4-8x10<sup>5</sup> cells are thawed on ice, supplemented with protease inhibitors (see above), boiled for 3 minutes in 0.35% SDS and chilled on ice. Samples are preincubated on a shaker for 1.5 hours at 4°C with 2-10 ul 2X of preimmune (or normal rabbit) serum and 2 mg Protein A-Sepharose (Sigma; prepared in 1X IPB), and insoluble immune removed by centrifugation. APP-or reporter epitopespecific antisera (0.1-10 ul) and 2 mg Protein A-Sepharose were similarly added and incubated overnight. Specific immune complexes were precipitated, washed 4 times with 0.25 ml 1 X IPB (with protease inhibitors), extracted with 20 ul Laemmli sample buffer (Laemmli (1970) Nature 227:680-685), boiled for 3 minutes and fractionated by electrophoresis on SDS-polyacrylamide-tris-glycine (Bio-Rad Laboratories, Richmond, VA) or SDS-polyacrylamide-tris-tricine Daiichi (Integrated Separation Systems, Natick, MA) gels. Gels are then treated with Enlightening Autoradiographic Enhancer (New England Nuclear, NEF-974) and dried in vacuo with heat and exposed to Kodak X-AR film at -70°C.

# Western (Immunoblot) Analysis

[0058] Lysate or 10X concentrated conditioned medium (Centricon 30 microconcentrator; Amicon, Beverly, MA) representing 4-8x10<sup>5</sup> cells are supplemented with an equal volume of 2X Laemmli sample buffer, boiled for 2 minutes, fractionated by electrophoresis on SDS-polyacrylamide-tris-glycine (Bio-Rad, XX) or SDS-polyacrylamide-tris-tricine Daiichi (Integrated Separation Systems, Natick, MA) gels and transblotted (Semi-Phor, Hoefer Instruments, San Francisco, CA) to Immobilon-P membrane (Millipore, Bedford, MA). Membranes are pre-blocked in 10 ml 5% non-fat dry milk/PBST (PBS with 0.02% Tween-20) for 45 minutes at room temperature prior to overnight incubation at 4°C with primary antisera (in fresh pre-blocking solution). Blots are then washed, incubated with secondary antibody, washed and developed for horseradish peroxidase activity as described (ECL Luminol Kit; Amersham, Arlington Heights, IL).

Peptide Mapping and Determination of the Site of Proteolytic Cleavage by Peptide Sequencing

[0059] The secretase clip site is determined essentially as described (Wang et al., (1991) J. Biol. Chem. 266: 16960-16964). Approximately 1X10<sup>6</sup> CHO cells stably expressing APP-REP are seeded in each 150 mm dish containing DMEM (complete with 200 ug/ml G418) and incubated for 36 hours. Cells are washed, preincubated for 6 hours in serum-free medium (MCDB 302 supplemented with antibiotics, L-glutamine (292 mg/l) and proline 12 mg/l (Sigma) to remove serum components, washed, and incubated for another 72 hours in fresh serum-free media.

**[0060]** Serum-free conditioned medium was pooled and cell debris was removed by centrifugation (10 minutes at 300xg, then 30 minutes at 100,000xg) and concentrated by acetone precipitation and fractionated by FPLC. Conditioned medium concentrate is loaded on an anion exchange column (Mono Q; source) and protein is eluted in 20 mM Tris (pH 7.4) over a 0-1M NaCl gradient. Fractions containing secreted APP are identified by immunoblotting (mono-

clonal antibody 22C11) and relevant samples pooled, desalted (NP-5 column; Pharmacia, Piscataway, NJ) and concentrated. Proteins are then denatured, treated with cyanogen bromide (in 10% trifluoroacetic acid) and peptides separated by high performance liquid chromatography (Vydac C<sub>18</sub> reverse-phase) attached to a FAB-MS unit. Relevant peaks derived from APP-REP BAP <sub>11-28</sub> are identified by locating these peaks uncommon to both proteins. The C-terminal peptides derived from APP-REP BAP <sub>11-28</sub> (predicted 14 amino acid) and APP-REP 751 (predicted 17 amino acid) are sequenced (MilliGen solid phase peptide sequencer; Millipore, Burlington, MA).

# **EXPERIMENTAL RESULTS**

30

35

50

55

10 Characterization of APP-REP Expression by Epitope Mapping

[0061] The APP-REP strategy (Figure 1) is a system for the expression of marked APP proteins in tissue culture cells in order to characterize the proteolytic cleavage events. The deletion of a 276 amino acid portion distinguishes the construct of this invention from endogenously expressed APP on the basis of size, and is predicted to increase the resolution of APP-REP fragments resulting from the proteolytic cleavage by secretase or other amyloidogenic, BAP-generating cleavage events. Substance P and Met-enkephalin marker epitopes strategically placed on either side of BAP enable the immunological detection of N- and C-terminal fragments, respectively, which result from proteolytic cleavage of APP-REP substrate.

[0062] APP-REP protein transiently expressed in COS-1 cells has been radiolabeled by metabolic incorporation of [35S]-methionine in a 60 minute pulse, immunoprecipitated with antisera, and size fractionated by gel electrophoresis as demonstrated in Figure 3. Immunoprecipitation with a panel of APP- and APP-REP-specific antisera which recognize epitopes mapping at various positions along APP-REP, reveals the presence of 2 proteins of ~63 kDa in cell lysates (including cytoplasmic and membrane associated proteins) as shown in Figure 3. The specific detection by antisera directed against the KPI domain, the carboxy-terminus of APP (M3, Figure 3A) and Met-enkephalin, as well as by the N-terminal 22C11 monoclonal in Western blot analysis (data not shown), suggests that both bands represent the full-length APP-REP protein. Although the 492 amino acid APP-REP is predicted to display a mobility of -49-54 KdA, the larger 63 and 76 kDa proteins are expected based on previous observations attributing the aberrant migration properties of APP, putatively to post-translational modification like tyrosine-sulfation, glycosylation and phosphorylation (Dyrks et al., (1988) EMBO J. 7:949-957; Weidemann et al., (1989) Cell 57:115-126.

[0063] Analysis of the conditioned medium (CM) collected from those same cells above indicates that an N-terminal fragment of APP-REP is released into the CM. Figure 3B reveals a shorter -67 kDa fragment immunoprecipitable from CM with KPI and SP antisera (and the 22C11 monoclonal by Western analysis), but not with several C-terminal APP or ME antisera. These data are consistent with the observations (Selkoe et al., (1988) P.N.A.S. 86:6338-6342; Palmert et al., (1989 a) P.N.A.S. U.S.A. 85:7341-7345), b) indicating that APP is a substrate for the proteolytic cleavage resulting in the secretion of an N-terminal fragment into CM, and a short membrane associated C-terminal fragment.

Pulse-Chase Analysis Reveals the Precursor/Product Relationship Between Cell Associated and Secreted Derivatives of APP-REP

[0064] To show that APP-REP undergoes post-translational modification accounting for the 2 cell associated proteins, and that the N-terminal APP-REP fragment released into CM is derived from one of these precursors, radiolabeled APP-REP is with a short 15 minute pulse and collected both cell lysates and CM at various chase intervals as shown in Figure 4. Immunoprecipitation analysis reveals that APP-REP initially migrates at -63 kDa and is rapidly "chased" up to ~76 kDa with conversion rate of less than 10-15 minutes (Figure 4A; also see Figure 5C for quantitative analysis), an observation which is consistent with the notion that APP-REP, like APP, is a substrate for post-translational modifications.

[0065] The -76 kDa APP-REP band (cell lysate) rapidly disappears (t <sup>1/2</sup> -20 minutes) (Figure 4A and 5C), followed by the appearance of a shorter -67 kDa band in the CM (Figure 4B and 5C). The released -67 kDa fragment accumulates rapidly and is relatively long lived (t 1/2 > 8 hours). The temporal pattern of intracellular APP-REP depletion, accumulation of a shorter ~67 kDa protein in CM, and the recognition of this protein only by antisera raised against N-terminal epitopes, is consistent with proteolytic cleavage of APP-REP which is similar to the normal, non-amyloidogenic, "secretase" activity which results in the release of an N-terminal APP fragment (Sisodia et al., (1990) Science 248:492-495.

Expression of APP-REP Derivatives Containing Altered BAP Sequences Does Not Prevent Proteolytic Cleavage

[0066] In an attempt to engineer non-cleavable substrates for secretase, APP-REP proteins are expressed (Figure 5A) either lacking the secretase "cleavage/recognition site" putatively encompassed by an residues BAP 11-28 (BAP $_{\Delta 11-28}$ pCLL604), or representing the BAP point mutation found in patients with HCHWA-D (BAP $_{E22Q}$ ,pCLL603).

The construct representing the BAPE22Q mutation results in secretion of an N-terminal fragment indistinguishable from the APP-REP protein (Figure 5C). Deletion of extracellular, juxtamembranous 18 aa (BAP $_{\Delta}$  11-28), however, still results in the secretion of an N-terminal APP-REP fragment into the CM (Figure 5B). A slightly faster migration of fragment derived from the deletion construct pCLL604 in comparison to that of wild-type pCLL602, is consistent with the 18 aa deletion and a corresponding loss of ~2 kDa (Figure 5C). Pulse-chase analyses (Figure 5D) indicate that expression of full-length precursor by each construct, proteolytic cleavable and the release of fragment into CM is both qualitatively and quantitatively similar to that of the wild-type APP-REP sequence. Chinese hamster ovary (CHO) cells stably expressing APP-REP display results similar to that of transiently expressing COS-1 cells (Figure 5E). Collectively, these data suggest that the cleavage in each case may be the result of similar biochemical events despite the difference in juxtamembranous sequences (Figure 5A).

Full-Length APP-REP Proteins Are Associated with Plasma Membrane Prior to Cleavage

[0067] In preliminary experiments, detection of the amino-terminal APP-REP fragment in CM and not in cell lysates, suggests that the putative secretase activity might be plasma membrane-associated. One prediction of this notion is that an N-terminal portion of APP-REP might be (partially) localized to the extracellular environment prior to cleavage. In order to test this hypothesis, CHO cells stably expressing APP-REP (pCLL602) are subjected to lactoperoxidase-catalyzed iodination to radiolabel only extracellular proteins associated with the cell surface, and CM and cell lysates were analyzed immediately following iodination or after a 10 minute incubation. Presence of the ~76 kDa APP-REP band in cell lysate should indicate that at least a portion of full-length APP-REP is poised extracellularly in association with cell membrane. Detection of both, a reduced fraction of the ~76 kDa band in the cell lysate and a corresponding increased fraction of ~67 kDa fragment in CM following the "release" incubation, would suggest that the extracellular portion of APP-REP is cleaved.

Peptide Sequencing to Determine the Site of Proteolysis

[0068] Fragment secreted into serum-free media derived from CHO cells stably expressing APP-REP with wild-type or BAP 11-28 sequences has been analyzed to determine the actual site of proteolytic cleavage as shown in Figure 6. Peptide mapping by tryptophan-specific cleavage with BNPS-skatole is used to roughly determine the approximate position of cleavage in each molecule. Western blot analysis using SP antisera following BNPS-skatole treatment (Figure 6B) reveals fragments whose lengths of -10.5 and -9.5 kDa, corresponding to wild type and BAP <sub>11-28</sub>respectively, confirming that cleavage occurs in the C-terminal portion of the PN-2-like protein as expected (Figure 6A). To determine the actual position of cleavage, secreted fragment is partially purified, treated with cyanogen bromide and relevant C-terminal peptides derived from APP-REP wild type.

### DISCUSSION

10

25

30

35

40

50

55

[0069] The expression of a truncated form of APP-751, namely APP-REP 751 (pCLL602) is examined and its normal cleavage by secretase. Comparison of the nontransfected cells and those transfected with APP-REP 751, in both COS-1 transient and CHO stable expression systems, show the production of shorter secreted protein derived from APP-REP. Furthermore, upon a prolonged exposure of the fluorogram only one band is observed in condition medium. Epitope mapping with antibodies to N- and C-terminal domains of APP-REP and amino acid sequencing suggest post-translational cleavage at a site similar to that reported for intact APP protein and other truncated APP constructs similar to that reported for intact APP protein and other truncated APP constructs. Pulse-chase experiments reveal post-translational modifications, believed to be similar to those described for the intact APP protein, in which a single ~63 kDa product is chased up to ~76 kDa in the first 30 minutes. Appearance of the ~76 kDa cell membrane associated protein precedes the release of a ~67 kDa product into the CM. The released form, which is not observed in the cell lysate fraction, steadily accumulates in the conditioned medium well after the ~76 kDa band has begun to disappear suggesting a precursor-product relationship. These data indicate that the APP-REP protein is a good representation of the naturally occurring APP with respect to post-translational synthesis, processing, and stability in a tissue culture system.

**[0070]** Epitope mapping of APP-REP 751 mutants suggest that BAP  $_{E22Q}$ , as well as the BAP  $_{\Delta11-28}$  deletion constructs, are initially expressed as larger proteins of predicted lengths which subsequently are cleaved to release N-terminal fragments into the CM. The pulse-chase experiments indicate the cell-associated and secreted forms accumulate with similar kinetics.

### TABLE 1

# Construction of APP-REP Partials

Α. pSK(+) Amino-Terminal Constructs: Cloning of APP Isoform and Reporter Epitope (EcoRI-HindIII Fragments)

	Plasmid	APP Isoform	Reporter Epitope
	Name	(EcoRI-XhoI Fragment)	(XhoI-
15	<u> HindIII</u>	Fragment)	
15	pCLL983	APP-695	Substance P*
	pCLL935	APP-751	Substance P
	pCLL934	APP-770**	Substance P
20	pCLL913	APP-770#	Substance P

# Notes:

5

10

25

30

35

- Substance P is a peptide containing 11 residues with the amino acid sequence of RPKPQQFFGLM.
- 5' untranslated sequences derived from the shorter APP-770 cDNA form.
- 5' untranslated sequences derived from the longer APP-751 cDNA form.
- pSL301 Carboxy-Terminal Constructs: Cloning of BAP-Encoding APP Reporter Epitope Fusions (HindIII-BamHI/SalI Fragment) в.

	Plasmid	Met-Enkephalin (ME)	
	Name	Fusion at end of:	Name of Variation
	pCLL947	Full-Length APP	APP-BAP-APP-ME
45	pCLL914	Transmembrane Domain	APP-BAP-TM-ME
	pCLL937	BAP	APP-BAP-ME

55

# TABLE 1 Construction of APP-REP Partials

(Continued)

c.	pSL301 C	arbox	y-Term:	inal	Full-	-Length	APP	-ME	2
	Construc	ts:	Introdu	actio	n of	Mutatio	ons	in	BAP
	(HindIII	-BamH	I/SalI	Frag	ment)				

Plasmid	Met-Enkephalin	
Name	Fusion at End of:	Name of Variation
pCLL949	E to Q substitution at	BAP E22Q
	BAP aa#22	
pCLL957	G to A substitution at	BAP-vaal1-28
	BTaa#10, deletion of BAP	
	AA#11-28 and creation of	
	NdeI site	

5		Assembly of APP-REP Full-Length Constructs Containing Substance P and Met-Enkephalin Reporter Epitopes and BAP or a Variation of BAP
10		ngth Cons Met-Enkey Variatio
15	TABLE 2	Full-Ler e P and BAP or a
20	TA	APP-REP Substanc
25		Assembly of APP-REP Full-Length Constructs Containing Substance P and Met-Enkephalin oorter Epitopes and BAP or a Variation of I
30		Ass Cor Report

Restriction	Fragment	(C-Terminus)	pcLL947	pcll947	pcrr947	pcLL949	pcLL949	pcll949		pcLL957	pcrr957	pcLL957	
	Plasmid	(N-Terminus)	pcLL983	pcll935	pcLL934	pcLL983	pcrr935	pCLL934		pcLL983	pcLL935	pcll934	
	Construct	Name/Variation	APP-REP-695	APP-REP-751	APP-REP-770	APP-REP-695/BAPE to Q PCLL983	APP-REP-751/BAPE to Q pcLL935	APP-REP-770/BAPE to Q		$APP-REP-695/BAP_{\Delta aa11-28}$	APP-REP-751/BAP Ann 1-28	APP-REP-770/BAP Age11-28	
	Plasmid	Name	pcll618	pcLL964	pcLL962	pcLL619	pcLL989	pcLL987	•	pcLL620	$pclbe{clbe}$	pcLL988	

TABLE 3

5

10

15

20

25

30

35

40

45

50

55

and Human Growth Hormone (hGH) into pcDNA-1-Neo[XS] Subcloning of APP-REP Full-Length Constructs

Source of Insert	p0GH*	Synthetic Fragment**	pcLL964	pcLL989	pcll990	pcLL962	pcLL987	pcLL988
Construct Name (in pcDNA-1-neo)	pcDNA-1-neo-hGH	pcDNA-1-neo[XS]	APP-REP-751	APP-REP-751/BAP $_{ m E}$ to $_{ m Q}$	APP-REP-751/BAP	APP-REP-770	APP-REP-770/BAPE to Q	APP-REP-770/BAP _aa11-28
Plasmid <u>Name</u>	pcLL600	pcLL601	pcLL602	pcLL603#	pcll604#	pcll605	pcLL606	pcLL607

# Notes:

- The HindIII-EcoRI (blunt-ended) fragment encoding hGH sequences of pOHG (Nichols Diagnostics) was subcloned into the HindIII-EcoRI (blunt-ended) sites of pcDNA-1-neo. \*
- several with polylinker was replaced XbaI site and introduced synthetic fragment which destroyed the original The HindIII-XbaI fragment of the pcDNA-1-neo unique sites (HindIII-BamHI-XbaI-XhoI-SalI). \*
- Also created by an alternative strategy using the same pSK(+) plasmids. **#**

TABLE 4
"Secretase-Minus" APP-REP Constructs
Engineered by Oligonucleotide-Directed Mutagenesis

** 00		31844 E		31844 F		31844 G		31844 H	
Percent** Secretion		100		0		10-20		10-20	
	20	TTT	Ţ	TTT	Ħ	TTT	[IL	TTT	ഥ
nce Type	19	TTC	[z.	TTC	দ	TTC	ഥ	555	а
eque 711d	17 18	GTG	>	GTG	>	GTG	>	GTG	>
BAP S		TTG	1	TTG	ы	$\mathbf{T}\mathbf{T}\mathbf{G}$	1	$\mathbf{T}\mathbf{T}\mathbf{G}$	ı
d J ed	_	_		_	_	_		_	_
Mutated BAP Sequence Compared to Wild Type	16	AAA	×	GAG	ы	GTG	>	AAA	×
ž Ö	15	CAA	α	CAA	ø	CAA	ŏ	CAA	ø
	14	CAT	H	CAT	H	CAT	H	CAT	H
Mutation <u>Identity</u>		BAP*		PCLL608 BAP-16KE		BAP-16KV		BAP-19FP	
Plasmid Name		pcLL602		pcll608		pcll609		pcLL610	

Notes:

Wild-type BAP

% secretion relative to wild type BAP sequence as determined by Sisodia.

# TABLE 5 APP-REP Constructs Modeling APP Mutations Associated with Diseases Involving BAP Deposition

# APP "717" MUTATIONS

10			// AP	P Tra	nsmer	nbran	ne Do	main	/		
	4	[BAP]									
			711	712	713	714	715	716	717	718	719
			[40	41	42]	1					
15	pCLL602	APP*	GTC	ATA	GCG	ACA	GTG	ATC	GTC	ATC	ACC-
			V	I	A	T	V	I	A	I	T
	pCLL611	717VI**	GTC	ATA	GCG	ACA	GTG	ATC	<u>A</u> TC	ATC	ACC
20			v	I	A	T	v	I	I	I	T
	pCLL612	717VG@	GTC	ATA	GCG	ACA	GTG	ATC	G <u>G</u> C	ATC	ACC.
			V	I	A	T	V	I	G	I	T.
25	pCLL613	717VF\$	GTC	ATA	GCG	ACA	GTG	ATC	TTC	ATC	ACC-
			A	I	A	T	V	I	F	I	1''

# TABLE 5 (continued)

DUTCH DISEASE

V (secretase clip)

10

15

	686	687	:	688	689	690	691	692	693	694
	[15	16	:	17	18	19	20	21	22	23]
pCLL602 BAP*	CAA	AAA	:	TTG	GTG	TTC	TTT	GCG	GAA	GAT
								_	_	
	Q	K	:	L	V	F	F	A	E	D

20

pCLL606#

K :

V

F

A

Q

D

# Notes:

# APP-REP-751 and -770 derived BAP-22EQ constructs.

\*\* Goate et al. (1991) Nature, 349:704-706; Yoshioka et al. (1991) BBRC 178:1141-1146; Naruse et al. (1991) Lancet 337:978-979.

30

25

- Chartier-Harlin <u>et al.</u> (1991) Nature <u>353</u>:844-846.
- Murrell <u>et al.</u> (1991) Science <u>254</u>:97-99.

35

# Claims

- 40 1. A nucleic acid molecule encoding an amyloid precursor mutein, which comprises a nucleic acid sequence encoding at least one marker, the entire β-amyloid protein domain (BAP) or variants BAP<sub>E22Q</sub> having an E to Q substitution at BAP amino acid #22 or BAP<sub>Δaa11-28</sub> and an amyloid precursor protein from which a block of 276 amino acids has been deleted.
- **2.** The nucleic acid molecule of claim 1, wherein the nucleic acid molecule is a nucleic acid molecule selected from the group consisting of DNA, cDNA or RNA.
  - 3. The nucleic acid molecule of claim 1, wherein the nucleic acid molecule is selected from the group consisting of pCLL964 (ATCC deposit no.: 68974) and pCLL602 (ATCC deposit no.: 68971).

- 4. The nucleic acid molecule of claim 1, wherein the amyloid precursor protein encoded by the nucleic acid sequence comprises 695, 751 or 770 amino acids prior to the deletion of the block of 276 amino acids.
- 5. A nucleic acid molecule encoding an amyloid precursor protein which comprises from the 5' end to the 3' end a nucleic acid sequence encoding a marker and an amyloid precursor protein comprising 695, 751 or 770 amino acids from which a block of 276 amino acids has been deleted, and which excludes the β-amyloid protein domain.
  - 6. The nucleic acid molecule of claim 5, wherein the nucleic acid molecule is pCLL935 (ATCC deposit no.: 68972).

- 7. A nucleic acid molecule encoding an amyloid precursor protein which comprises from the 5' end to the 3' end a nucleic acid sequence encoding a marker and the β-amyloid protein domain variants BAP<sub>E22Q</sub> having an E to Q substitution at BAP amino acid #22 or BAP<sub>Aaa11-28</sub>.
- 8. A nucleic acid molecule encoding an amyloid precursor protein which comprises from the 5' end to the 3' end a nucleic acid sequence encoding Met-Enkephalin as a marker and the β-amyloid protein domain or variants BAP<sub>E22Q</sub> having an E to Q substitution at BAP amino acid #22 or BAP<sub>Δaa11-28</sub>
  - 9. The nucleic acid molecule of claim 8, wherein the nucleic acid molecule is pCLL947 (ATCC deposit no.: 68973).
  - 10. A vector comprising the nucleic acid molecule of claim 1, claim 5, claim 7 or claim 8.
  - 11. A host cell stably transformed or transfected by a vector comprising the nucleic acid molecule of claim 1, claim 5, claim 7 or claim 8.
  - 12. A recombinant polypeptide produced by the nucleic acid molecule of claim 1, claim 5, claim 7 or claim 8.
  - 13. A method of detecting the presence of the recombinant polypeptide of claim 12 in a sample, comprising the steps of:
    - (a) contacting an antibody directed to the marker and the sample under suitable conditions to favor the formation of an antibody-antigen complex, and
    - (b) detecting the presence of any complex so formed.
- **14.** A method of screening for a compound which inhibits or augments the formation of β-amyloid protein, comprising the steps of:
  - (a) measuring the amount of marker in a suitable medium containing transfected cells stably or transiently expressing the nucleic acid molecule of claim 1,
  - (b) treating said cells with the compound. and
  - (c) testing the medium for an increase in the amount of the marker.

# Patentansprüche

10

15

20

30

45

- Nukleinsäuremolekül, das für ein Amyloidvorläufermutein kodiert, umfassend eine Nukleinsäuresequenz, die für mindestens einen Marker, für die gesamte β-Amyloidproteindomäne (BAP) oder deren Varianten BAP<sub>E22Q</sub> mit einem E zu Q Austausch an BAP Aminosäure Nr. 22 oder BAP<sub>Δaa11-28</sub> und für ein Amyloidvorläuferprotein kodiert, von dem ein Block von 276 Aminosäuren deletiert wurde.
- Das Nukleinsäuremolekül von Anspruch 1, das aus der Gruppe bestehend aus DNA, cDNA oder RNA ausgewählt ist.
  - 3. Das Nukleinsäuremolekül von Anspruch 1, das aus der Gruppe bestehend aus pCLL964 (ATCC Hinterlegung Nr. 68974) und pCLL602 (ATCC Hinterlegung Nr. 68971) ausgewählt ist.
  - Das Nukleinsäuremolekül von Anspruch 1, wobei das von der Nukleinsäuresequenz kodierte Amyloidvorläuferprotein 695, 751 oder 770 Aminosäuren vor der Deletion des Blocks von 276 Aminosäuren umfasst.
- 5. Nukleinsäuremolekül, das für ein Amyloidvorläuferprotein kodiert, umfassend vom 5' zum 3' Ende eine Nuklein-50 säuresequenz, die für einen Marker und für ein Amyloidvorläuferprotein kodiert, das 695, 751 oder 770 Aminosäuren umfasst, von dem ein Block von 276 Aminosäuren deletiert wurde und das die β-Amyloidproteindomäne nicht umfasst.
  - 6. Das Nukleinsäuremolekül von Anspruch 5, das pCLL935 (ATCC Hinterlegung Nr. 68972) ist.
  - 7. Nukleinsäuremolekül, das für ein Amyloidvorläuferprotein kodiert, umfassend vom 5' zum 3' Ende eine Nukleinsäuresequenz, die für einen Marker und für die β-Amyloidproteindomän-Varianten BAP<sub>E22Q</sub> mit einem E zu Q Austausch an BAP Aminosäure Nr. 22 oder BAP<sub>Δaa11-28</sub> kodiert.

- 8. Nukleinsäuremolekül, das für ein Amyloid-Vorläufer-Protein kodiert, umfassend vom 5' zum 3' Ende eine Nukleinsäuresequenz, die für Met-Enkephalin als Marker und für die β-Amyloidproteindomän-Varianten BAP<sub>E22Q</sub> mit einem E zu Q Austausch an BAP Aminosäure Nr. 22 oder BAP<sub>Aaa11-28</sub> kodiert.
- 5 9. Das Nukleinsäuremolekül von Anspruch 8, das pCLL947 (ATCC Hinterlegung Nr. 68973) ist.
  - 10. Vektor umfassend das Nukleinsäuremolekül von Anspruch 1, 5, 7 oder 8.
- **11.** Wirtszelle, die mit einem Vektor umfassend das Nukleinsäuremolekül von Anspruch 1, 5, 7 oder 8 stabil transformiert oder transfiziert ist.
  - 12. Rekombinantes Polypeptid, das mit dem Nukleinsäuremolekül von Anspruch 1, 5, 7 oder 8 hergestellt ist.
- **13.** Verfahren zur Detektion der Anwesenheit des rekombinanten Polypeptids von Anspruch 12 in einer Probe, das die folgenden Schritte umfasst:
  - (a) Kontaktieren eines gegen den Marker und die Probe gerichteten Antikörpers unter geeigneten Bedingungen, um die Bildung eines Antikörper-Antigen-Komplexes zu begünstigen, und
  - (b) Detektieren eines so gebildeten Komplexes.
  - **14.** Verfahren zum Screening nach einer Verbindung, die die Bildung des β-Amyloidproteins inhibiert oder verstärkt, umfassend die Schritte:
    - (a) Messen der Markermenge in einem geeigneten Medium, das transfizierte Zellen enthält, die stabil oder transient das Nukleinsäuremolekül von Anspruch 1 exprimieren,
    - (b) Behandeln der Zellen mit der Verbindung und
    - (c) Testen des Mediums auf eine Zunahme der Markermenge.

### 30 Revendications

20

25

35

45

- 1. Molécule d'acide nucléique codant pour une mutéine précurseur d'amyloïde, comprenant une séquence d'acide nucléique codant pour au moins un marqueur, le domaine complet de la protéine amyloïde β (BAP) ou le variant BAP<sub>E22Q</sub> comportant un remplacement de E par Q à l'aminoacide N° 22 de la protéine BAP ou BAP<sub>Δaa11-28</sub>, et une protéine précurseur d'amyloïde dont un segment de 276 aminoacides a été supprimé.
- 2. Molécule d'acide nucléique selon la revendication 1, dans laquelle la molécule d'acide nucléique est une molécule d'acide nucléique choisie parmi un ADN, un ADNc ou un ARN.
- 40 3. Molécule d'acide nucléique selon la revendication 1, dans laquelle la molécule d'acide nucléique est choisie parmi pCLL964 (numéro de dépôt ATCC 68974) et pCLL602 (numéro de dépôt ATCC 68971).
  - 4. Molécule d'acide nucléique selon la revendication 1, dans laquelle la protéine précurseur d'amyloïde codée par la séquence d'acide nucléique comprend 695, 751 ou 770 aminoacides avant la suppression du segment de 276 aminoacides.
    - 5. Molécule d'acide nucléique codant pour une protéine précurseur d'amyloïde comprenant de l'extrémité 5' à l'extrémité 3', une séquence d'acide nucléique codant pour un marqueur et une protéine précurseur d'amyloïde comprenant 695, 751 ou 770 aminoacides dont un segment de 276 aminoacides a été supprimé, et qui exclut le domaine de la protéine amyloïde β.
    - Molécule d'acide nucléique selon la revendication 5, dans laquelle la molécule d'acide nucléique est pCLL935 (numéro de dépôt ATCC 68972).
- 7. Molécule d'acide nucléique codant pour une protéine précurseur d'amyloïde comprenant de l'extrémité 5' à l'extrémité 3', une séquence d'acide nucléique codant pour un marqueur et le variant de domaine de la protéine amyloïde β BAP<sub>E22Q</sub> comportant un remplacement de E par Q à l'aminoacide N° 22 de la protéine BAP ou BAP<sub>Δaa11-28</sub>.

- 8. Molécule d'acide nucléique codant pour une protéine précurseur d'amyloïde comprenant de l'extrémité 5' à l'extrémité 3', une séquence d'acide nucléique codant pour la mét-encéphaline en tant que marqueur, et le domaine de la protéine amyloïde β ou le variant BAP<sub>E22Q</sub> comportant un remplacement de E par Q à l'aminoacide N° 22 de la protéine BAP, ou BAP<sub>Δaa11-28</sub>.
- Molécule d'acide nucléique selon la revendication 8, dans laquelle la molécule d'acide nucléique est pCLL947 (numéro de dépôt ATCC 68973).
- 10. Vecteur comprenant la molécule d'acide nucléique de la revendication 1, de la revendication 5, de la revendication7 ou de la revendication 8.
  - 11. Cellule hôte transformée ou transfectée de manière stable par un vecteur comprenant la molécule d'acide nucléique de la revendication 1, de la revendication 5, de la revendication 7 ou de la revendication 8.
- 15 **12.** Polypeptide recombinant produit par la molécule d'acide nucléique de la revendication 1, de la revendication 5, de la revendication 7 ou de la revendication 8.
  - **13.** Procédé de détection de la présence du polypeptide recombinant de la revendication 12 dans un échantillon, comprenant les étapes consistant :
    - (a) à mettre en contact un anticorps dirigé contre le marqueur et l'échantillon dans des conditions appropriées pour favoriser la formation d'un complexe anticorps-antigène, et
    - (b) à détecter la présence d'un complexe ainsi formé.

5

20

30

35


40

45

50

- 25 **14.** Procédé de sélection d'un composé empêchant ou augmentant la formation de la protéine amyloide β, comprenant les étapes consistant :
  - (a) à mesurer la quantité de marqueur dans un milieu approprié contenant des cellules transfectées de manière stable ou exprimant temporairement la molécule d'acide nucléique de la revendication 1,
  - (b) à traiter lesdites cellules avec le composé, et
  - (c) à tester le milieu à l'égard d'un accroissement de la quantité du marqueur.

Figure 1.



# Figure 2.




Figure 3.




Figure 4.





Figure 5.







Figure 5.

C.



D.




Figure 5.

E.



# Figure 6.




FIGURE 6.



```
SEQUENCE: pCLL602 (APP-REP 751 protein)
           pcDNA-I-neo (Invitrogen)
VECTOR:
           pcDNA-I-neo-XS (JSJ modified polylinker to permit directional
             subcloning into XbaI-SalI sites)
INSERT:
           xbaI-SalI fragment encoding APF-REP from pCLL964
                                                                 16-1711
                                                                  2-47
SEQUENCE: 5' polylinker:
                                                                  2-15
              HindIII-XbaI from pcDNA-I-neo-XS
              XbaI-EcoRI from pBluescript SK+
           APP-REP 751:
              Amino-terminal partial from pCLL935):
                                                                 48-1314
                 5' untranslated APP cDNA (from EcoRI)
                                                                 48-195
                 N-terminal APP (to XhoI)
                                                                196-1273
                 Substance P marker (XhoI to HindIII)
                                                               1274-1314
              Carboxy-terminal partial from pCLL947): 1314-1671
C-terminal APP and BAP (from novel HindIII) 1314-1656
                 Met-enkephalin marker (plus stop codon)
                                                               1657-1674
           3' polylinker:
              BamHI-SalI from pSL301
                                                               1674-1711
              SalI-end of sequence from pcDNA-I-neo-XS
                                                               1712-1721
                                    30
              10
                          20
                                                 40
                                                            50
      AAGCTTGGGG ATCCGCTCTA GAACTAGTGG ATCCCCCGGG CTGCAGGAAT
      TTCGAACCCC TAGGCGAGAT CTTGATCACC TAGGGGGCCC GACGTCCTTA
                          70
              60
                                     80
                                                 90
                                                           100
      TCGGGGGGGG CAGCGGTAGG CGAGAGCACG CGGAGGAGCG TGCGCGGGGC
      AGCCCCCCC GTCGCCATCC GCTCTCGTGC GCCTCCTCGC ACGCGCCCCG
                                    130
                         120
      CCCGGGAGAC GGCGGCGGTG GCGGCGGGG CAGAGCAAGG ACGCGGCGGA
      GGGCCCTCTG CCGCCGCCAC CGCCGCGCCC GTCTCGTTCC TGCGCCGCCT
                         170
                                    180
                                                190
      TCCCACTCGC ACAGCAGCGC ACTCGGTGCC CCGCGCAGGG TCGCG
      AGGGTGAGCG TGTCGTCGCG TGAGCCACGG GGCGCGTCCC AGCGC
                                                                240
                                     220
                                                   230
         200
                       210
      ATG CTG CCC GGT TTG GCA CTG CTC CTG CTG GCC GCC TGG ACG GCT
      TAC GAC GGG CCA AAC CGT GAC GAG GAC GAC CGG CGG ACC TGC CGA
      Met Leu Pro Gly Leu Ala Leu Leu Leu Leu Ala Ala Trp Thr Ala>
                                            270
                 250
                              260
      CGG GCG CTG GAG GTA CCC ACT GAT GGT AAT GCT GGC CTG CTG GCT GAA
      GCC CGC GAC CTC CAT GGG TGA CTA CCA TTA CGA CCG GAC GAC CGA CTT
      Arg Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu>
```

FIGURE 7

296			300			310				320 330					
CCC GGG Pro	GTC	TAA	CGG	TAC	AAG	ACA	೦೦ಡ	TCT	CAC	TTG	TAC	etg	™àC	TTA	GTC CAG Val>
34	.0		3	350		360					70		:	380	
CAG	AAT	GGG	AAG	TGG	GAT	TCA	GAT	CCA	TCA	GGG	ACC	λλλ	ACC	TGC	ATT ·
GTC															TAA Ile>
94	390	<b>G</b> -y	-7-	-	-	565			761	G-Y			• • • • •		
	390 400 * * ACC AAG GAA GGC A			*	410				420 *				4.	30	
GAT ÇTA															
															Glu>
	4	40			450			4 (	50		4	170			480
CTG															
GAC Leu															GTC Gln>
									510	<b>V</b>		52		•	
	490				500			TGC AAG ACC CAT				*			
				CGG											
															Phe>
530			540			5	50			560			570		
				CGC											
															GAA Leu>
58			_	590	-		600	_			10			520	
	*			*	<b>300</b>		*	<b></b>	<b>63.6</b>	<i>-</i>	*	100		*	CMM
GAG	CAA	GGA	CIG	AAG TTC	ACG	TTT	AAG	AAT	GTG	GTÇ	CTC	TCC	TAĈ	CTA	CAA
Leu	Val	Pro	Asp	Lys	Cys	Lys	Phe	Leu	His	Gln	Glu	yrğ	Met	<b>A</b> 8p	Val>
	630			6	40		(	650 *			660			67	70 *
TGC	GAA	ACT	CAT	CTT	CAC	TGG	CAC	ACC	GIC	GCC	AAA	GAG	ACA	TGC	AGT
				GAA Leu											Ser>
	,	680			690		•	7	700 710				720		
				AAC											
CTC Glu	TTC Lys	TCA Ser	TGG Thr	TTG Asn	AAC Leu	GTA His	CTG Asp	ATG Tyr	CCG	TAC Met	AAC Leu	GAC Leu	GGG Pro	ACG Cys	CCT Gly>

	730				740 *				٥٥،	7 6 Q					
ATT (	CTG	TTC	AAG	GCT	CCC	CAT	CTC	AAA	CAC	ACA	ACG	CGT	GA,C	CGA	
770			780			75	0		Ε	00			810		
GAA : CTT : Glu :	TCA	CTG	TTA	CAC	CTA	AGA	CGA	CTA	CGC	CTC	CTC	CTA	CTG	AGC	CTA
82		•		130	840			•	850			•	sp Asp Ser Asp>		
GTC :	TGG ACC	ACC	CCG	CCT	CGT	CTG	TGT	CTG	ATA	CGT	CTA	CCC	TCA	CTT	GAC CTG Asp>
	870			8 6	30		1	390			900			9:	10
AAA ( TTT ( Lys )	ÇAT	CAT	CTT	CAT	CGT	CTC	CTC	CTT	CTT	CAC	CGA	CTC	CAC	CTT	
	920				930	930 94 *				950					960
GAA CTT Glu	CTT	CGG	CTA	CTA	CTG	CTC	CIG	CTA	CTC	CTA	CCA	CTA	CTC	CAT	
		9	70		9	80			990			100	00		
GAA CTT Glu	CTC	CGA	CIC	CTT	GGG	ATG	CIT	CIT	CGG	TGT	CTC	TCT	tgg	TGG	
1010		:	1020			103	90		10	40		1	1050		
ATT TAA Ile	CGG	tgg	TGG	igg	tgg	tgg	tgg	tgt	CTC	λGλ	CAC	CTT	CTC	CAC	GTT CAA Val>
106	0		10	70		:	1080			109	90		11	00	
CGA GCT Arg	CTC	CAC	ACG	AGA	CTT	GTT	CGG	CTC	TGC	CCC	GGC	ACG	GCT	CGT	ATG TAC Met>
1	110			112	20 113			130	1140				1150		
ATC TAG Ile	AGG	GCG	ACC	ATG	AAA	CTA	CAC	TGA	CTT	CCC	TTC	ACA	CGG	GGT	TTC AAG Phe>

```
1170
       1160
                                   1180
                                               1150
                                                             1200
 TIT TAC GGC GGA TGT GGC GGC AND CGU ALC AND TIT GAC AMA GAA GAG
 AAA ATG CCG CCT ACA CCG CCG TTG GCC TTG TTG AAA CTG TGT CTT CTC
 Phe Tyr Gly Gly Cys Gly Gly Asn Arg Asn Asn Phe Asp Thr Glu Glu>
 TAC TGC ATG GCC GTG TGT GGC AGC GCC ATT CCT ACA ACA GCA GCC AGT
 ATG ACG TAC CGG CAC ACA CCG TCG CGG TAA GGA TGT TGT CGT CGG TCA
 Tyr Cys Met Ala Val Cys Gly Ser Ala Ile Pro Thr Thr Ala Ala Ser>
1250
                                        1280
 ACC CCT GAT GCC GTT GAC AAG TAT CTC GAG CGG CCC AAG CCC CAG CAG
 TGG GGA CTA CGG CAA CTG TTC ATA GAG CTC GCC GGG TTC GGG GTC GTC
 Thr Pro Asp Ala Val Asp Lys Tyr Leu Glu Arg Pro Lys Pro Gln Gln>
  1300
                1310
                             1320
 TTC TTT GGC CTG ATG GGA AGC TTG ACA AAT ATC AAG ACG GAG GAG ATC
 AAG AAA CCG GAC TAC CCT TCG AAC TGT TTA TAG TTC TGC CTC CTC TAG
 Phe Phe Gly Leu Met Gly Ser Leu Thr Asn Ile Lys Thr Glu Glu Ile>
                   1360
                                1370
     1350
 TOT GAA GTG AAG ATG GAT GCA GAA TTC CGA CAT GAC TCA GGA TAT GAA
 AGA CIT CAC TIC TAC CIA CGT CIT AAG GCT GIA CIG AGT CCT ATA CIT
 Ser Glu Val Lys Met Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu>
        1400
                     1410
                                   1420
                                                1430
 GTT CAT CAT CAR ARA TTG GTG TTC TTT GCA GAR GAT GTG GGT TCA AAC
 CAA GTA GTA GTT TTT AAC CAC AAG AAA CGT CTT CTA CAC CCA AGT TTG
 Val His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn>
                                     1470
                        1460
                                                   1480
           1450
 AAA GGT GCA ATC ATT GGA CTC ATG GTG GGC GGT GTT GTC ATA GCG ACA
  TIT CCA CGT TAG TAA CCT GAG TAC CAC CCG CCA CAA CAG TAT CGC TGT
 Lya Gly Ala Ile Ile Gly Leu Met Val Gly Gly Val Val Ile Ala Thr>
                                        1520
                                                     1530
1490
             1500
                           1510
  GTG ATC GTC ATC ACC TTG GTG ATG CTG AAG AAA CAG TAC ACA TCC
  CAC TAG CAG TAG TGG AAC CAC TAC GAC TTC TTC TTT GTC ATG TGT AGG
  Val Ile Val Ile Thr Leu Val Met Leu Lys Lys Lys Gln Tyr Thr Ser>
                                           1570
                             1560
  ATT CAT CAT GGT GTG GTG GAG GTT GAC GCC GCT GTC ACC CCA GAG GAG
  TAA GTA GTA CCA CAC CAC CTC CAA CTG CGG CGA CAG TGG GGT CTC CTC
  Ile His His Gly Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu>
```

GGC CAC CTG TCC AAG ATG CAG CAG AAC GGC TAC GAA AAT CCA ACC TAC GGG GTG GAC AGG TTC TAC GCC GTC TTG CCG ATG CTT TTA GGT TGG AAG ATG His Leu Ser Lys Met Gln Gln Asn Gly Tyr Glu Asn Fro Thr Tyr>

1540

1650

1660

1670

1680

AAG TTC TTT GAG CAG ATG CAG AAC TAT GGG GGC TTC ATG TAG GATCA TTC AAG AAA CTC GTC TAC GTC TTG ATA CCC CCG AAG TAC ATC CTAGGT Lys Phe Phe Glu Gln Met Gln Asn Tyr Gly Gly Phe Met \*\*\*

1690

1700

1710

1720

TATATAGGGC CCGGGTTAT AATTACCTCA GGTCGACCTA GA ATATATCCCG GGCCCAATA TTAATGGAGT CCAGCTGGAT CT

```
Total of 12 files.
RMRD3>TYPE APP770.
                          3353 bp ss-mRNA
                                                       PRT
                                                                  15-JUN-1989
FOCUS
            HUMAFPA4
Human amyloid A4 mRNA, complete cds.
            Y00264
ACCESSION
            amyloid fibril protein; cell surface glycoprotein.
KEYWORDS
SOURCE
            human (Homo sapiens).
  ORGANISM Homo sapiens
            Eukaryota; Animalia; Metazoa; Chordata; Vertebrata; Mammalia;
            Theria; Eutheria; Primates; Haplorhini; Catarrhini; Hominidae.
            1 (bases 1 to 3353; enum. -146 to 3207, no zero)
Kang, J., Lemaire, H.G., Unterbeck, A., Salbaum, J.M., Masters, C.L.,
REFERENCE
  AUTHORS
            Grzeschik, K.-H., Multhaup, G., Beyreuther, K. and Mueller-Hill, B.
The precursor of Alzheimer's disease amyloid A4 protein resembles a
  TITLE
            cell-surface receptor
            Nature 325, 733-736 (1987)
  JOURNAL
  STANDARD simple automatic
            2 (bases 1 to 3353; enum. 1 to 3353)
REFERENCE
            Mueller Hill, B.
  AUTHORS
            Unpublished (1987) Submitted to the EMBL data library.
  JOURNAL
  STANDARD
            simple automatic
             *source: tissue=cortex of brain; *source: developmental
COMMENT
             stage=5-month-old aborted fetus;
                EMBL features not translated to GenBank features:
               key
SITE
                           from
                                     to
                                               description
                           3080
                                   3085
                                               polyA signal
                                   3094
                           3089
                                               polyA signal
                SITE
                SITE
                           3331
                                   3336
                                               polyA signal
                                              polyA site
               POLYA
                                   3353
                           3353
                                   description
FEATURES
                from to/span
                                   amyloid A4 /nomgen="APP" /map="21q21.2"
                 147
                         2234
    pept
                                   /hgml_locus_uid="LG0136J"
                          745 c
                                    867 a
                                             819 t
                 922 a
BASE COUNT
ORIGIN
      App770. Length: 3353 May 29, 1990 11:30 Check: 6510
       1 AGTTTCCTCG GCAGCGGTAG GCGAGAGCAC GCGGAGGAGC GTGCGCGGGG
      51 CCCCGGGAGA CGCCGCGGT GGCGGCGCG GCAGAGCAAG GACGCGGCGG
     101 ATCCCACTCG CACAGCAGCG CACTCGGTGC CCCGCGCAGG GTCGCGATGC
     151 TGCCCGGTTT GGCACTGCTC CTGCTGGCCG CCTGGACGGC TCGGGCGCTG
     201 GAGGTACCCA CTGATGGTAA TGCTGGCCTG CTGGCTGAAC CCCAGATTGC
     251 CATGTTCTGT GGCAGACTGA ACATGCACAT GAATGTCCAG AATGGGAAGT
     301 GGGATTCAGA TCCATCAGGG ACCAAAACCT GCATTGATAC CAAGGAAGGC
     351 ATCCTGCAGT ATTGCCAAGA AGTCTACCCT GAACTGCAGA TCACCAATGT
     401 GGTAGAAGCC AACCAACCAG TGACCATCCA GAACTGGTGC AAGCGGGGCC
     451 GCAAGCAGTG CAAGACCCAT CCCCACTTTG TGATTCCCTA CCGCTGCTTA
     501 GTTGGTGAGT TTGTAAGTGA TGCCCTTCTC GTTCCTGACA AGTGCAAATT
     551 CTTACACCAG GAGAGGATGG ATGTTTGCGA AACTCATCTT CACTGGCACA
     601 CCGTCGCCAA AGAGACATGC AGTGAGAAGA GTACCAACTT GCATGACTAC
     651 GGCATGTTGC TGCCCTGCGG AATTGACAAG TTCCGAGGGG TAGAGTTTGT
     701 GTGTTGCCCA CTGGCTGAAG AAAGTGACAA TGTGGATTCT GCTGATGCGG
```

### FIGURE 8

751	AGGAGGATGA	CTCGGATGTC	TGGTGGGGCG	GAGCAGACAC	AGA TATGCA
801	GATGGGAGTG	AAGACAAAGT	AGTAGAAGTA	GCAGAGGAGG	AAGAAGTGGC
851	TGAGGTGGAA	GAAGAAGAAG	CCGATGATGA	CGAGGACGAT	GAGGATGGTG
901	ATGAGGTAGA	GGAAGAGGCT	GAGGAACCCT	ACGAAGAAGC	CACAGAGAGA
951	ACCACCAGCA	TTGCCACCAC	CACCACCACC	ACCACAGAGT	CTGTGGAAGA
1001	GGTGGTTCGA	GTTCCTACAA	CAGCAGCCAG	TACCCCTGAT	GCCGTTGACA
1051	AGTATCTCGA	GACACCTGGG	GATGAGAATG	AACATGCCCA	TTTCCAGAAA
1101	GCCAAAGAGA	GGCTTGAGGC	CAAGCACCGA	GAGAGAATGT	CCCAGGTCAT
1151	GAGAGAATGG	GAAGAGGCAG	AACGTCAAGC	AAAGAACTTG	CCTAAAGCTG
1201	ATAAGAAGGC	AGTTATCCAG	CATTTCCAGG	AGAAAGTGGA	ATCTTTGGAA
1251	CAGGAAGCAG	CCAACGAGAG	ACAGCAGCTG	GTGGAGACAC	ACATGGCCAG
1301	AGTGGAAGCC	ATGCTCAATG	ACCGCCGCCG	CCTGGCCCTG	GAGAACTACA
1351	TCACCGCTCT	GCAGGCTGTT	CCTCCTCGGC	CTCGTCACGT	GTTCAATATG
1401	CTAAAGAAGT	ATGTCCGCGC	AGAACAGAAG	GACAGACAGC	ACACCCTAAA
1451	GCATTTCGAG	CATGTGCGCA	TGGTGGATCC	CAAGAAAGCC	GCTCAGATCC
1501	GGTCCCAGGT	TATGACACAC	CTCCGTGTGA	TTTATGAGCG	CATGAATCAG
1551	TCTCTCTCCC	TGCTCTACAA	CGTGCCTGCA	GTGGCCGAGG	AGATTCAGGA
1601	TGAAGTTGAT	GAGCTGCTTC	AGAAAGAGCA	AAACTATTCA	GATGACGTCT
1651	TGGCCAACAT	GATTAGTGAA	CCAAGGATCA	GTTACGGAAA	CGATGCTCTC
1701	ATGCCATCTT	TGACCGAAAC	GAAAACCACC	GTGGAGCTCC	TTCCCGTGAA
1751	TGGAGAGTTC	AGCCTGGACG	ATCTCCAGCC	GTGGCATTCT	TTTGGGGCTG
1801	ACTCTGTGCC	AGCCAACACA	GAAAACGAAG	TTGAGCCTGT	TGATGCCCGC
1851	CCTGCTGCCG	ACCGAGGACT	GACCACTCGA	CCAGGTTCTG	GGTTGACAAA
1901	TATCAAGACG	GAGGAGATCT	CTGAAGTGAA	GATGGATGCA	GAATTCCGAC
1951	atgactcagg	ATATGAAGTT	CATCATCAAA	AATTGGTGTT	CTTTGCAGAA
2001	GATGTGGGTT	CAAACAAAGG	TGCAATCATT	GGACTCATGG	TGGGCGGTGT
2051	TGTCATAGCG	ACAGTGATCG	TCATCACCTT	GGTGATGCTG	AAGAAGAAAC
2101	AGTACACATC	CATTCATCAT	GGTGTGGTGG	AGGTTGACGC	CGCTGTCACC
2151	CCAGAGGAGC	GCCACCTGTC	CAAGATGCAG	CAGAACGGCT	ACGAAAATCC
2201	AACCTACAAG	TTCTTTGAGC	AGATGCAGAA	CT	
				AGACCCCC	GCCACAGCAG
2251	CCMGMG233C=	maa.a.a	*****		
4431	CCICIGAAGT	TGGACAGCAA	AACCATTGCT	TOMOTHOCOM	TOGGTGTCCW

2001	TTTATAGAAT	AATGTGCGAA	GAAACAAACC	CGTTTTATGA	TTTACTCATT
2351	ATCGCCTTTT	GACAGCTGTG	CTGTAACACA	AGTAGATGCC	TGAACTTGAA
2401	TTAATCCACA	CATCAGTAAT	GTATTCTATC	TCTCTTTACA	TITTGGTCTC
2451	TATACTACAT	TATTAATGGG	TTTTGTGTAC	TGTAAAGAAT	TTAGCTGTAT
2501	CAAACTAGTG	CATGAATAGA	TTCTCTCCTG	ATTATTTATC	ACATAGCCCC
2551	TTAGCCAGTT	GTATATTATT	CTTGTGGTTT	GTGACCCAAT	TAAGTCCTAC
2601	TTTACATATG	CTTTAAGAAT	CGATGGGGGA	TGCTTCATGT	GAACGTGGGA
2651	GTTCAGCTGC	TTCTCTTGCC	TAAGTATTCC	TTTCCTGATC	ACTATGCATT
2701	TTAAAGTTAA	ACATTTTTAA	GTATTTCAGA	TGCTTTAGAG	AGATTTTTT
2751	TCCATGACTG	CATTTTACTG	TACAGATTGC	TGCTTCTGCT	ATATTTGTGA
2801	TATAGGAATT	AAGAGGATAC	ACACGTTTGT	TTCTTCGTGC	CTGTTTTATG
2851	TGCACACATT	AGGCATTGAG	ACTTCAAGCT	TTTCTTTTTT	TGTCCACGTA
2901	TCTTTGGGTC	TTTGATAAAG	AAAAGAATCC	CTGTTCATTG	TAAGCACTTT
2951	TACGGGGCGG	GTGGGGAGGG	GTGCTCTGCT	GGTCTTCAAT	TACCAAGAAT
3001	TCTCCAAAAC	AATTTTCTGC	AGGATGATTG	TACAGAATCA	TTGCTTATGA
3051	CATGATCGCT	TTCTACACTG	TATTACATAA	ATAAATTAAA	TAAAATAACC
3101	CCGGGCAAGA	CTTTTCTTTG	AAGGATGACT	ACAGACATTA	AATAATCGAA
3151	GTAATTTTGG	GTGGGGAGAA	GAGGCAGATT	CAATTTTCTT	TAACCAGTCT
3201	GAÁGTTTCAT	TTATGATACA	AAAGAAGATG	AAAATGGAAG	TGGCAATATA
3251	AGGGGATGAG	GAAGGCATGC	CTGGACAAAC	CCTTCTTTTA	AGATGTGTCT
3301	TCAATTTGTA	TAAAATGGTG	TTTTCATGTA	AATAAATACA	TTCTTGGAGG
3351	AGC				

RMRD3>